Inhibition of Skp2 suppresses the proliferation and invasion of osteosarcoma cells

Ding,Lu; Li,Rong; Han,Xiaoping; Zhou,Yubo; Zhang,Hua; Cui,Yong; Wang,Wu; Bai,Jingping

doi:10.3892/or.2017.5713

Inhibition of Skp2 suppresses the proliferation and invasion of osteosarcoma cells

Authors:
- Lu Ding
- Rong Li
- Xiaoping Han
- Yubo Zhou
- Hua Zhang
- Yong Cui
- Wu Wang
- Jingping Bai
View Affiliations

Affiliations: Department of Orthopedics, Tumor Hospital Affiliated to Xinjiang Medical University, Xinshi, Urumqi, Xinjiang 830000, P.R. China, Department of Maternal, Child and Adolescent Health, College of Public Health, Xinjiang Medical University, Xinshi, Urumqi, Xinjiang 830000, P.R. China, Department of Orthopedics, Fifth Affiliated Hospital, Xinjiang Medical University, Xinshi, Urumqi, Xinjiang 830000, P.R. China, Department of Orthopedics, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Xinshi, Urumqi, Xinjiang, P.R. China
Published online on: June 12, 2017 https://doi.org/10.3892/or.2017.5713
Pages: 933-940

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is a common bone tumor that mainly affects children and young adults. S-phase kinase‑associated protein 2 (Skp2) has been characterized to play a critical oncogenic role in a variety of human malignancies. However, the biological function of Skp2 in OS remains largely obscure. In the present study, we elucidated the role of Skp2 in cell growth, cell cycle, apoptosis and migration in OS cells. We found that depletion of Skp2 inhibited cell growth in both MG-63 and SW 1353 cells. Moreover, we observed that depletion of Skp2 triggered cell apoptosis in two OS cell lines. Furthermore, downregulation of Skp2 induced cell cycle arrest in the G0/G1 phase in OS cells. Notably, our wound healing assay results revealed that inhibition of Skp2 suppressed cell migration in OS cells. Invariably, our western blot results demonstrated that depletion of Skp2 in OS cells inhibited activation of pAkt and increased p27 expression in OS cells, suggesting that Skp2 exerted its oncogenic function partly through the regulation of Akt and p27. Our findings revealed that targeting Skp2 could be a promising therapeutic strategy for the treatment of OS.

View Figures

View References

1	Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Vos HI, Coenen MJ, Guchelaar HJ and Loo Te DM: The role of pharmacogenetics in the treatment of osteosarcoma. Drug Discov Today. 21:1775–1786. 2016. View Article : Google Scholar : PubMed/NCBI
4	Kushlinskii NE, Fridman MV and Braga EA: Molecular mechanisms and microRNAs in osteosarcoma pathogenesis. Biochemistry. 81:315–328. 2016.PubMed/NCBI
5	Li C, Cong Y, Liu X, Zhou X, Zhou G, Lu M, Shi X and Wu S: The progress of molecular diagnostics of osteosarcoma. Front Biosci. 21:20–30. 2016. View Article : Google Scholar
6	Tao J, Jiang MM, Jiang L, Salvo JS, Zeng HC, Dawson B, Bertin TK, Rao PH, Chen R, Donehower LA, et al: Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 26:390–401. 2014. View Article : Google Scholar : PubMed/NCBI
7	Carrano AC, Eytan E, Hershko A and Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1:193–199. 1999. View Article : Google Scholar : PubMed/NCBI
8	Tsvetkov LM, Yeh KH, Lee SJ, Sun H and Zhang H: p27^Kip1 ubiquitination and degradation is regulated by the SCF^Skp2 complex through phosphorylated Thr187 in p27. Curr Biol. 9:661–664. 1999. View Article : Google Scholar : PubMed/NCBI
9	Yu ZK, Gervais JL and Zhang H: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21^CIP1/WAF1 and cyclin D proteins. Proc Natl Acad Sci USA. 95:11324–11329. 1998. View Article : Google Scholar : PubMed/NCBI
10	Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K and Nakayama KI: Degradation of p57^Kip2 mediated by SCF^Skp2-dependent ubiquitylation. Proc Natl Acad Sci USA. 100:10231–10236. 2003. View Article : Google Scholar : PubMed/NCBI
11	Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM and Tindall DJ: Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA. 102:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
12	Wang H, Cui J, Bauzon F and Zhu L: A comparison between Skp2 and FOXO1 for their cytoplasmic localization by Akt1. Cell Cycle. 9:1021–1022. 2010. View Article : Google Scholar : PubMed/NCBI
13	Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, et al: Targeted disruption of Skp2 results in accumulation of cyclin E and p27^Kip1, polyploidy and centrosome overduplication. EMBO J. 19:2069–2081. 2000. View Article : Google Scholar : PubMed/NCBI
14	Kratzat S, Nikolova V, Miething C, Hoellein A, Schoeffmann S, Gorka O, Pietschmann E, Illert AL, Ruland J, Peschel C, et al: Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies. PLoS One. 7:e374332012. View Article : Google Scholar : PubMed/NCBI
15	Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, et al: Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood. 112:1960–1970. 2008. View Article : Google Scholar : PubMed/NCBI
16	Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T and Nakayama KI: Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell. 6:661–672. 2004. View Article : Google Scholar : PubMed/NCBI
17	Minamishima YA and Nakayama K and Nakayama K: Recovery of liver mass without proliferation of hepatocytes after partial hepatectomy in Skp2-deficient mice. Cancer Res. 62:995–999. 2002.PubMed/NCBI
18	Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ and Germain D: Skp2B attenuates p53 function by inhibiting prohibitin. EMBO Rep. 11:220–225. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C and Zhang H: Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res. 63:1583–1588. 2003.PubMed/NCBI
20	Sistrunk C, Kim SH, Wang X, Lee SH, Kim Y, Macias E and Rodriguez-Puebla ML: Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27^Kip1 accumulation. Am J Pathol. 182:1854–1864. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pagano M: Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell. 14:414–416. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kullmann MK, Grubbauer C, Goetsch K, Jäkel H, Podmirseg SR, Trockenbacher A, Ploner C, Cato AC, Weiss C, Kofler R, et al: The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle. 12:2625–2635. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lim MS, Adamson A, Lin Z, Perez-Ordonez B, Jordan RC, Tripp S, Perkins SL and Elenitoba-Johnson KS: Expression of Skp2, a p27^Kip1 ubiquitin ligase, in malignant lymphoma: Correlation with p27^Kip1 and proliferation index. Blood. 100:2950–2956. 2002. View Article : Google Scholar : PubMed/NCBI
24	Schüler S, Diersch S, Hamacher R, Schmid RM, Saur D and Schneider G: SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. Int J Oncol. 38:219–225. 2011.PubMed/NCBI
25	Chan CH, Lee SW, Wang J and Lin HK: Regulation of Skp2 expression and activity and its role in cancer progression. Sci World J. 10:1001–1015. 2010. View Article : Google Scholar
26	Hulit J, Lee RJ, Li Z, Wang C, Katiyar S, Yang J, Quong AA, Wu K, Albanese C, Russell R, et al: p27^Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res. 66:8529–8541. 2006. View Article : Google Scholar : PubMed/NCBI
27	Fujita T, Liu W, Doihara H, Date H and Wan Y: Dissection of the APC^Cdh1-Skp2 cascade in breast cancer. Clin Cancer Res. 14:1966–1975. 2008. View Article : Google Scholar : PubMed/NCBI
28	Voduc D, Nielsen TO, Cheang MC and Foulkes WD: The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol. 39:1431–1437. 2008. View Article : Google Scholar : PubMed/NCBI
29	Liu J, Wei XL, Huang WH, Chen CF, Bai JW and Zhang GJ: Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS One. 7:e526752012. View Article : Google Scholar : PubMed/NCBI
30	Wei S, Chu PC, Chuang HC, Hung WC, Kulp SK and Chen CS: Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. PLoS One. 7:e472982012. View Article : Google Scholar : PubMed/NCBI
31	Zhao H, Bauzon F, Fu H, Lu Z, Cui J, Nakayama K, Nakayama KI, Locker J and Zhu L: Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell. 24:645–659. 2013. View Article : Google Scholar : PubMed/NCBI
32	Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K and Mori M: Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: Modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 62:3819–3825. 2002.PubMed/NCBI
33	Benevenuto-de-Andrade BA, León JE, Carlos R, Delgado-Azañero W, Mosqueda-Taylor A and Paes-de-Almeida O: Immunohistochemical expression of Skp2 protein in oral nevi and melanoma. Med Oral Patol Oral Cir Bucal. 18:e388–e391. 2013. View Article : Google Scholar : PubMed/NCBI
34	Qu X, Shen L, Zheng Y, Cui Y, Feng Z, Liu F and Liu J: A signal transduction pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with progression in human melanoma. J Invest Dermatol. 134:159–167. 2014. View Article : Google Scholar : PubMed/NCBI
35	Chen G, Cheng Y, Zhang Z, Martinka M and Li G: Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS One. 6:e175782011. View Article : Google Scholar : PubMed/NCBI
36	Lu M, Ma J, Xue W, Cheng C, Wang Y, Zhao Y, Ke Q, Liu H, Liu Y, Li P, et al: The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res. 15:679–687. 2009. View Article : Google Scholar : PubMed/NCBI
37	Xu HM, Liang Y, Chen Q, Wu QN, Guo YM, Shen GP, Zhang RH, He ZW, Zeng YX, Xie FY, et al: Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer. 30:204–212. 2011. View Article : Google Scholar : PubMed/NCBI
38	Fang FM, Chien CY, Li CF, Shiu WY, Chen CH and Huang HY: Effect of S phase kinase-associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 73:202–207. 2009. View Article : Google Scholar : PubMed/NCBI
39	Liao QD, Zhong D and Chen Q: Protein expression of Skp2 in osteosarcoma and its relation with prognosis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 33:606–611. 2008.(In Chinese). PubMed/NCBI
40	Xu D, Li CF, Zhang X, Gong Z, Chan CH, Lee SW, Jin G, Rezaeian AH, Han F, Wang J, et al: Skp2-macroH2A1-CDK8 axis orchestrates G2/M transition and tumorigenesis. Nat Commun. 6:66412015. View Article : Google Scholar : PubMed/NCBI
41	Lee SW, Li CF, Jin G, Cai Z, Han F, Chan CH, Yang WL, Li BK, Rezaeian AH, Li HY, et al: Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol Cell. 57:1022–1033. 2015. View Article : Google Scholar : PubMed/NCBI
42	Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T and Costa RH: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
43	Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y and Komiya S: Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer. 100:1957–1965. 2009. View Article : Google Scholar : PubMed/NCBI
44	Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, Kunigou O and Komiya S: Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer. 9:52010. View Article : Google Scholar : PubMed/NCBI
45	Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, Nagano S, Takizawa T, Nakashima K, Komiya S and Setoguchi T: Role of GLI2 in the growth of human osteosarcoma. J Pathol. 224:169–179. 2011. View Article : Google Scholar : PubMed/NCBI
46	Gao D, Inuzuka H, Tseng A, Chin RY, Toker A and Wei W: Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 11:397–408. 2009. View Article : Google Scholar : PubMed/NCBI
47	Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, et al: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 11:420–432. 2009. View Article : Google Scholar : PubMed/NCBI
48	Zhang H: Skip the nucleus, AKT drives Skp2 and FOXO1 to the same place? Cell Cycle. 9:868–869. 2010. View Article : Google Scholar : PubMed/NCBI
49	Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, et al: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 149:1098–1111. 2012. View Article : Google Scholar : PubMed/NCBI
50	Singh R, Sran A, Carroll DC, Huang J, Tsvetkov L, Zhou X, Sheung J, McLaughlin J, Issakani SD, Payan DG, et al: Developing structure-activity relationships from an HTS hit for inhibition of the Cks1-Skp2 protein-protein interaction. Bioorg Med Chem Lett. 25:5199–5202. 2015. View Article : Google Scholar : PubMed/NCBI
51	Oh M, Lee JH, Moon H, Hyun YJ and Lim HS: A chemical inhibitor of the Skp2/p300 interaction that promotes p53-mediated apoptosis. Angew Chem Int Ed Engl. 55:602–606. 2016. View Article : Google Scholar : PubMed/NCBI
52	Gao JK, Wang LX, Long B, Ye XT, Su JN, Yin XY, Zhou XX and Wang ZW: Arsenic trioxide inhibits cell growth and invasion via down-regulation of Skp2 in pancreatic cancer cells. Asian Pac J Cancer Prev. 16:3805–3810. 2015. View Article : Google Scholar : PubMed/NCBI
53	Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH, Chen LT, Kung HJ, et al: Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 6:6684–6707. 2015. View Article : Google Scholar : PubMed/NCBI
54	Huang HC, Lin CL and Lin JK: 1,2,3,4,6-penta-O-galloyl-β-_D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. J Agric Food Chem. 59:6765–6775. 2011. View Article : Google Scholar : PubMed/NCBI
55	Jia T, Zhang L, Duan Y, Zhang M, Wang G, Zhang J and Zhao Z: The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway. Cancer Cell Int. 14:1262014. View Article : Google Scholar : PubMed/NCBI
56	Sun SH, Huang HC, Huang C and Lin JK: Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. Eur J Pharmacol. 690:22–30. 2012. View Article : Google Scholar : PubMed/NCBI
57	Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D and Zi X: Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget. 6:41809–41824. 2015.PubMed/NCBI
58	Wang L, Ye X, Cai X, Su J, Ma R, Yin X, Zhou X, Li H and Wang Z: Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells. Oncotarget. 6:18027–18037. 2015. View Article : Google Scholar : PubMed/NCBI
59	Chen X, Li Q, He Y, Du H, Zhan Z, Zhao H, Shi J, Ye Q and Hu J: 15,16-dihydrotanshinone I induces apoptosis and inhibits the proliferation, migration of human osteosarcoma cell line 143B in vitro. Anticancer Agents Med Chem. 15:12015. View Article : Google Scholar
60	Li Z, Liu H, Li B, Zhang Y and Piao C: Saurolactam inhibits proliferation, migration, and invasion of human osteosarcoma cells. Cell Biochem Biophys. 72:719–726. 2015. View Article : Google Scholar : PubMed/NCBI